TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Medical Device Regulation implementation – One year to go!

Medical Device Regulation implementation – One year to go!

Medical Device Regulation implementation – One year to go!

As highlighted in our recent  article “ The Medical Device Regulation and COVID-19”  the date of application of the MDR has been delayed by 1 year, from the 26th May 2020 to the 26th May 2021. As this delay was only agreed in April of this year, the majority of device manufacturers will have been well underway with their MDR transition preparation. By now, most, if not all manufacturers will know if the new device classification rules will impact their products. They should also have prepared for the change in the rules for claiming equivalence, and obtained additional clinical data where needed, in the cases where the original device technical file is not available. Clinical Evaluation Reports are being updated and Post-Market Surveillance Systems have been created.

However, there are some subjects which may seem less critical or are less obvious, but that also warrant significant time and consideration:

  • Unique Device Identification – whilst the Eudamed database has been delayed until 2022, so no device registration is required, and the UDI does not need to appear on the labelling until 2021-2025 depending upon classification, the UDI and Basic UDI-DI still need to be included within the Technical Documentation. Management of UDI requires cross-organisational cooperation, so we recommend that discussions are started soon, if they have not already.
  • QMS – Many manufacturers assume that if they are complaint with ISO 13485:2016 that their Quality Management System will meet the requirements of the MDR. However, there are a number of requirements listed in Article 10 of the MDR (General obligations of manufacturers) that are not included in the QMS standard. Examples include strategy for regulatory compliance, UDI verification and handling communication with stakeholders.
  • Restricted substances – MDR and RoHS Directive (Restriction of the use of certain Hazardous Substances Directive 2011 / 65 / EU need to be complied with. Both include substance restrictions, but the approaches used are very different. The MDR Annex I section 10.4 requires substitution of carcinogens, reproductive toxins and mutagens (CMR) of category 1A and 1B as well as endocrine disrupting (ED) substances, of which the EU has two classifications, 1 and 2, unless the manufacturer can show that the use of the substance is justified from a benefit-risk analysis. The scope of these requirements is limited to materials that come into contact directly with patients or in contact with solids, fluids or gases that are administered or re-administered to patients.
  • Economic Operators – The MDR identifies a number of Economic Operators, and their responsibilities are covered in articles 10-16. Depending upon the location of the manufacturer, there may be a necessity for new agreements to cover the MDR and the new requirements and liability. Multinational organisations should also pay attention, that whilst they may not need an external Authorised Representative or Importer, if the Legal Manufacturer is based outside of the EU, it is expected that the required verification to be completed by the AR and Importer are still carried out.

The team at Pharmalex are ready and able to assist with all Medical Device activities, whether they relate to QMS challenges, Technical Documentation preparation or understanding the implications of the requirements of the MDR. Please contact us – contact@pharmalex.com

Related posts
Digital Technology Pharma
Contamination Control
8th April 2021
uk pharma
Rules on Ownership of Medicinal Product stock distributed in Great Britain
7th April 2021
compliance pharma
GET SMART: reliable analytical results & continuous regulatory compliance!
30th March 2021
Archemin Merger
PharmaLex expands France BENELUX region
16th March 2021
Challenges of Advanced Therapy Medicinal Products (ATMP's)
Challenges of Advanced Therapy Medicinal Products (ATMPs)
16th March 2021
ERA merger
PharmaLex broadens biopharma expertise
5th March 2021
Search
Upcoming Webinars

April 27th, 2021

Orphan Drugs for Rare Diseases in Children – Considerations for PIPs and PSPs

3 PM CET

May 12th, 2021

Bayesian Approaches for Incorporating Natural History Data in Studies of Rare and Pediatric Disease

4 PM CET

Upcoming Events

June 14 - 17th, 2021

BIO International Convention 2021

June 27 - July 1st, 2021

DIA Annual Meeting 2021

September 22 - 24th, 2021

TOPRA Symposium 2021

Categories
  • All News
  • Webinars
  • Events
Archive
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We needed a partner to help us obtain device approval. PharmaLex have not only helped us achieve this but are now providing on-going post-marketing surveillance support. We would highly recommend them to anyone who needs specialist expertise.

    Med Device company, US
    Senior Regulatory Affairs Director
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.